Literature DB >> 33413406

Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.

Alberto Galizzi1, Mara Bagardi2, Angelica Stranieri2, Anna Maria Zanaboni3, Dario Malchiodi3, Vitaliano Borromeo2, Paola Giuseppina Brambilla2, Chiara Locatelli2.   

Abstract

BACKGROUND: Chronic renin-angiotensin-aldosterone system (RAAS) activation in course of heart diseases contributes to cardiac remodeling and heart failure. Myxomatous mitral valve disease (MMVD) is characterized by different stages of severity and trend of RAAS activity during the course of the disease is still uncertain. The urinary aldosterone-to-creatinine ratio (UAldo:C) has been proven to reflect RAAS activation in dogs and might be a useful marker in monitoring therapy and disease progression, but data about this parameter need to be expanded. The objective of this study was to evaluate the UAldo:C in healthy dogs and dogs with naturally occurring MMVD, and to investigate the relationships between this parameter and clinical, echocardiographic and laboratory variables.
RESULTS: The study population consisted of 149 dogs: 49 healthy and 100 MMVD dogs (45 stage B1, 13 stage B2 and 42 stage C). Urinary aldosterone-to-creatinine ratio was not significantly different among healthy and MMVD dogs of any stages. Breed, sex and age showed a significant impact on UAldo:C. In particular, Chihuahua and Cavalier King Charles spaniel showed significantly higher UAldo:C than other breeds, as well as intact females than other genders. In stage C dogs, UAldo:C appeared to be increased by spironolactone and was positively associated with furosemide dose (P = 0.024). Aldosterone breakthrough (ABT) appeared to occur in 36% (8/22) of stage C dogs not receiving spironolactone. A significant positive association between UAldo:C and left atrium-to-aortic root ratio (LA/Ao) was found.
CONCLUSIONS: Individual factors such as breed, sex and age appeared to influence UAldo:C, and therapy seemed to add further variability. In the light of these results, comparing the UAldo:C of a single patient with a population-based reference value might lead to wrong interpretations and an individual monitoring should be considered. The prevalence of ABT in the present study (36%) was in line with those previously reported. However, due to the high individual variability of UAldo:C found in the study, even this result should be re-evaluated in the setting of an individual longitudinal approach. The positive association between UAldo:C and LA/Ao supports the mutual relationship between RAAS and cardiac remodeling.

Entities:  

Keywords:  Aldosterone; Dog; LA/Ao; MMVD; RAAS; UAldo:C

Mesh:

Substances:

Year:  2021        PMID: 33413406      PMCID: PMC7792040          DOI: 10.1186/s12917-020-02716-6

Source DB:  PubMed          Journal:  BMC Vet Res        ISSN: 1746-6148            Impact factor:   2.741


  87 in total

1.  Allometric scaling of M-mode cardiac measurements in normal adult dogs.

Authors:  Craig C Cornell; Mark D Kittleson; Paul Della Torre; Jens Häggström; Christophe W Lombard; Henrik D Pedersen; Andrea Vollmar; Aaron Wey
Journal:  J Vet Intern Med       Date:  2004 May-Jun       Impact factor: 3.333

2.  Effects of dilated cardiomyopathy on the renin-angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs.

Authors:  A Tidholm; J Häggström; K Hansson
Journal:  Am J Vet Res       Date:  2001-06       Impact factor: 1.156

Review 3.  Aldosterone and inflammation.

Authors:  Kimberly C Gilbert; Nancy J Brown
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-06       Impact factor: 3.243

4.  Neuroendocrine changes in Dachshunds with mitral valve prolapse examined under different study conditions.

Authors:  H D Pedersen; L H Olsen; T Mow; N J Christensen
Journal:  Res Vet Sci       Date:  1999-02       Impact factor: 2.534

Review 5.  Neuroendocrine evaluation of cardiac disease.

Authors:  D David Sisson
Journal:  Vet Clin North Am Small Anim Pract       Date:  2004-09       Impact factor: 2.093

6.  Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs.

Authors:  Marisa K Ames; Clarke E Atkins; Seunggon Lee; Andrea C Lantis; James R zumBrunnen
Journal:  Am J Vet Res       Date:  2015-12       Impact factor: 1.156

Review 7.  The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure.

Authors:  C G Brilla; H Rupp; R Funck; B Maisch
Journal:  Eur Heart J       Date:  1995-12       Impact factor: 29.983

8.  Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement.

Authors:  Kerstin Hansson; Jens Häggström; Clarence Kvart; Peter Lord
Journal:  Vet Radiol Ultrasound       Date:  2002 Nov-Dec       Impact factor: 1.363

9.  Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.

Authors:  Nicolas Girerd; Peter S Pang; Karl Swedberg; Angela Fought; Mary J Kwasny; Haris Subacius; Marvin A Konstam; Aldo Maggioni; Mihai Gheorghiade; Faiez Zannad
Journal:  Eur J Heart Fail       Date:  2013-06-19       Impact factor: 15.534

10.  Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.

Authors:  Darcy Adin; Kari Kurtz; Clarke Atkins; Mark G Papich; Shelly Vaden
Journal:  J Vet Intern Med       Date:  2019-11-26       Impact factor: 3.333

View more
  1 in total

1.  Protective Effects of Fucoxanthin on Hydrogen Peroxide-Induced Calcification of Heart Valve Interstitial Cells.

Authors:  Yi-Fen Chiang; Chih-Hung Tsai; Hsin-Yuan Chen; Kai-Lee Wang; Hsin-Yi Chang; Yun-Ju Huang; Yong-Han Hong; Mohamed Ali; Tzong-Ming Shieh; Tsui-Chin Huang; Ching-I Lin; Shih-Min Hsia
Journal:  Mar Drugs       Date:  2021-05-26       Impact factor: 5.118

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.